Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
The success, and limitations,
of trastuzumab for HER2-positive breast cancer have
inspired the creation of a series
of novel drugs. Investigators
in the Women's Cancers
Program (WCP) are leading or
offering clinical trials of five
classes of these new therapies.
Finally, studies are planned with pertuzimab, a "monoclonal"
antibody (an antibody duplicated millions of times
over) that prevents the HER2 receptor from joining to its
sister receptors HER1 and HER3. Without such a connection,
HER2 cannot activate cell growth.
"In cases of advanced HER2-positive breast cancer,
these potential therapies may provide great hope for
women whose cancer is resistant to trastuzumab,"
says Eric Winer, MD, director of the Breast Oncology
Center within the WCP. "For women with early breast
tumors, they may offer an increased number of options if
the disease progresses."
2009 Turning Point